Investor Presentaiton

DS-5670 Current development status Development of COVID-19 vaccine progressed FY2021 FY2022 H1 H2 H1 H2 Ph1/2 study Ph2 Ph1/2/3 booster vaccination Planning Ph3 study in Japan (JP) Dose setting ■Development of booster vaccination - Ph1/2/3 study Part 1 was completed - - Efficacy: Data on neutralizing activities four weeks after receiving the vaccination show that the efficacy of DS-5670 is comparable to or higher than an approved mRNA vaccine in both healthy adult and elderly subjects - Safety: no serious adverse reactions at the injection site or systemic ones were observed. · Part 2 was initiated in May 2022 - Commercialization in Japan is expected within CY2022 Part 1 Dose confirmation study (528 subjects) Part 2 Active-controlled, non-inferiority study (4500 subjects) Confirmatory study of booster effect comparing to approved COVID-19 mRNA vaccine in subjects who completed the initial vaccination (1st & 2nd shots) of approved COVID-19 mRNA vaccine Daiichi-Sankyo 34

View entire presentation